ISRCTN15592135已完成2 期
Application of peripheral blood-derived stem cell/progenitor cell (CD34?) therapy on chronic kidney disease: Phase 2 clinical trial
Ministry of Science and Technology, Taiwan0 个研究点目标入组 52 人开始时间: 2018年8月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 52
研究概览
简要总结
2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32297703/ (added 20/01/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 20-80 years old
- •2. Renal failure due to hypertension
- •3. Receiving optimal medical therapy (received optimal therapy for more than 12 weeks and have been evaluated by a nephrologist. Medication includes ACEI, ARB, DRI, beta-blocker or CCB. Blood pressure is less than 140/90 mmHg)
- •4. Renal function between chronic kidney disease (CKD) stage III-IV
- •5. Stable renal function maintained for 1 year before study (creatinine clearance rate between 15-60 ml/min and no significant changes)
排除标准
- •1. Pregnant or breastfeeding
- •2. Infected with HIV
- •3. Infected with HBV or HCV
- •4. Myocardial infarction within 3 months prior to study
- •5. Heart failure (functional class IV)
- •6. Malignant or hematological disease
- •7. Severe disease with lifespan less than 1 year
- •8. End stage renal disease
- •9. Creatinine clearance rate less than 15 ml/min
- •10. Kidney disease on only one side
- •11. Participating in other clinical trials
- •12. Unable to receive therapies used in this study
- •13. Organ transplantation
- •14. Autoimmune disease
研究者
相似试验
已完成
2 期
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related DonorsHematologic NeoplasmsAnemia, AplasticHemoglobinuria, ParoxysmalMultiple MyelomaNCT00618969University of Arizona2
终止
不适用
Stem Cell CollectionStem CellsNCT00316069National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)429
终止
不适用
Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal VolunteersNormal PhysiologyNCT01123499National Institute of Allergy and Infectious Diseases (NIAID)5
终止
3 期
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell TransplantationGraft Versus Host DiseaseLymphomaLeukemiaNCT00003056Baxalta now part of Shire105
已完成
2 期
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in RemissionAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid LeukemiaNCT00045435Fred Hutchinson Cancer Center17